Marker tumour response to Evans and Pasteur bacilie Calmette‐Guérin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)

Abstract

In multiple recurrent pTa or pT1 bladder tumours clearing the bladder of all except one marker tumour provides a safe and convenient way of measuring the response to intravesical therapy. No significant difference in efficacy or toxicity was detected between Evans BCG and Pasteur BCG.

The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer

“…In a 1994 Medical Research Council randomized marker lesion study, Fellows compared BCG Pasteur and Evans BCG [8]. In 99 patients, all papillary tumors but one were resected and a course of 6 BCG instillations was given.…”

Diagnosis and Treatment of Superficial Transitional Cell Carcinoma of the Bladder: Facts and Perspectives

“…In 1 patient the marker tumor progressed to T2. With BCG alone (34 patients treated with Evans-BCG (1-5 x 109 cfu) and 33 with Pasteur-BCG (1-3 X 109 cfu)) complete response (judged by ei ther cystoscopy or biopsy) was achieved in 24% with Evans-BCG and 42% with Pasteur-BCG, new occur rences with/without persistent marker lesion were ob served in 76 and 58%, respectively [59], Thus the principle of a marker-tumor study is an appropriate, feasible and safe way to evaluate the ablative effects of new agents. Promising drugs may thereafter be tested in phase III trials while expensive, ineffective drugs should be excluded from further investigation [60].…”

BCG in Perspective: Advances in the Treatment of Superficial Bladder Cancer

“…In a randomized comparison of Evans BCG and Pasteur BCG in 97 patients with a mark er tumour, complete response with no recurrence at other sites was seen in 24% given Evans BCG and 42% given Pasteur BCG, and complete regression of the marker tumour was seen in 48 and 63%, respectively (differences not statistically significant [14]). Similarly, no significant difference in tumour recurrence with RIVM BCG (29%) and Tice BCG (34%) prophylaxis was seen [11], Several studies looking at dose have been reported, with conflicting results.…”